I-Mab Q2 FY2024 earnings call

• Divested China operations on April 2, extinguished $183 million of redemption obligations in the transaction, and an additional $17 million post-second quarter, with remaining $15 million to be extinguished in September. • Established U.S.-based global biotech company, streamlined organization, and built a new U.S.-based leadership team including CFO Joe Skelton and CMO Phillip Dennis. • Transitioned to PWCUS as corporate auditor. • Advanced three oncology programs: uliledlimab, givastomig, and ragistomig, with significant progress in their clinical development and milestones.

No detailed financial performance for product segments in terms of absolute revenue and contribution % provided in the transcript.

• Expect to initiate the first patient dose in the uliledlimab plus pembro plus chemotherapy combination study in the first half of 2025. • Anticipate top line progression-free survival (PFS) data from the uliledlimab plus toripalimab randomized Phase II study conducted by collaborator TJ Bio in the second half of 2025. • Plan to present updated Phase I dose expansion data from givastomig at the ESMO 2024 meeting and expect top line data from the givastomig combo study in gastric cancers in the second half of 2025.

• Forward-looking statements include risks and uncertainties that can cause actual results to differ materially. • Market data used involves assumptions and limitations, and no independent source has verified estimates of potential market opportunities.

Q: On givastomig's ESMO update and comparison to Claudin 18.2 ADC landscape A: Data presented at ESMO will be from dose expansion cohorts with gastric cancer (approx. 30 patients) showing exquisite safety and notable ORR. Giva's tolerability makes it suitable for frontline combination with nivolumab and Folfox, differentiating from ADCs due to better toxicity profile for combination in frontline studies Q: Targeted finish date for transitioning to U.S.-based auditor and pipeline strategy A: Transition to PWCUS as auditor is complete; going burn rate lower due to streamlined organization; actively looking to enhance pipeline through external collaboration/licensing, focusing on oncology but open to adjacent modalities for near-term value inflection Q: Efficacy benchmarks for uliledlimab combination study and leveraging TJ Bio study data A: Benchmarks against Keynote 189; interested in outcomes from competitor studies to validate adenosine pathway; hope to see signals of benefit in CD73 positive patients from studies